Tiziana life sciences announces additional clinical improvements among multiple sclerosis patients in its expanded access program

New york, april 22, 2024 (globe newswire) -- tiziana life sciences, ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced additional positive clinical results from its intermediate sized expanded access program (eap) for non-active secondary progressive multiple sclerosis (na-spms) patients. the data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. fatigue is a debilitating symptom for many ms patients and is measured by the modified fatigue impact scale (mfis).
TLSA Ratings Summary
TLSA Quant Ranking